• Profile
Close

GW researchers develop testing program to study potency for neglected tropical disease vaccines

George Washington School of Medicine and Health Sciences News Mar 29, 2017

Researchers at the George Washington University (GW) have developed a way to test recombinant vaccines for their ability to stay effective after years of storage. This is an important next step in the development of a recombinant hookworm vaccine being developed at GW. The Na–GST–1/Alhydrogel® vaccine was shown to be stable and maintain immunogenicity during five years of storage between 35 and 46 degrees Fahrenheit (2 to 8 degrees Celsius).

Published in the journal PLOS Neglected Tropical Diseases, researchers have published methods and statistics that are typically proprietary information held by vaccine manufacturers.

“We wrote our paper almost like an instruction book on how to determine recombinant vaccine potency,” said Jeffrey Bethony, PhD, senior author and professor of microbiology, immunology, and tropical medicine at the GW School of Medicine and Health Sciences. “We think it’s important for researchers and vaccine manufacturers in low– and middle–income countries such as Brazil or Southeast Asia to know the key measures for vaccine product development.”

The hookworm vaccine has been tested in several Phase 1 clinical studies in healthy adults at GW, in Brazil, and in Gabon. The authors also are currently working on a controlled human hookworm infection model to accelerate hookworm vaccine development. Determining relative potency and functional assays is an important step in the vaccine development process.

“Vaccine work is team work. We work with biochemists, immunologists, biostatisticians, and more. We assembled a great team here at GW and believe that’s what this paper shows,” said Bethony. “Our hookworm vaccine has an excellent shelf life, which is good for where it will be used – in developing countries.”

Bethony works closely with David Diemert, MD, co–senior author and associate professor of microbiology, immunology, and tropical medicine at the GW School of Medicine and Health Sciences, to lead the hookworm vaccine development at GW. The team also includes Jill Breslford, Jordan Plieskatt, Jin Peng, Doreen Campbell, and Guangzhao Li, all researchers in the Department of Microbiology, Immunology, and Tropical Medicine at the GW School of Medicine and Health Sciences.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay